Cancer research, stimulated

The US federal agency tasked with tackling cancer has laid out a plan to double the number of cancer research projects it funds, prioritizing first-time grants to young researchers and emphasizing genomic approaches to understanding the disease. These goals are attainable, according to linkurl:John Niederhuber,;http://www.cancer.gov/aboutnci/directorscorner/jen director of the National Cancer Institute (NCI), thanks to an infusion of government funding from an increased annual budget and recent

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
The US federal agency tasked with tackling cancer has laid out a plan to double the number of cancer research projects it funds, prioritizing first-time grants to young researchers and emphasizing genomic approaches to understanding the disease.
These goals are attainable, according to linkurl:John Niederhuber,;http://www.cancer.gov/aboutnci/directorscorner/jen director of the National Cancer Institute (NCI), thanks to an infusion of government funding from an increased annual budget and recently awarded stimulus funds. But since stimulus funds must be spent within two years, Niederhuber said during a speech at the American Association for Cancer Research conference in Denver, the NCI is weighing grant awards carefully. "It falls to NCI to carefully calculate and thoughtfully assume the risks of initially funding some four-year grants with economic stimulus money, knowing that we will need to find additional resources for the out years," Niederhuber said, according to a linkurl:transcript;http://www.cancer.gov/newscenter/pressreleases/AACRspeech2009QandA of his speech. "I believe it falls, as well, to our grantees to come forward with only their strongest science." In 2009 the agency will be able to fund the top 16% of grant applications instead of only the top 12%--last year's payline--based on budgetary increases alone, Niederhuber said. The NCI may be able to fund 25% of applications with the added $1.3 billion that the agency is set to receive as part of the $10 billion in stimulus funding for the National Institutes of Health. But raising the payline is only half the story. "Economic stimulus funds give us the chance to be visionary," Niederhuber said, adding that the NCI will seek to fund more young, first-time investigators, and will emphasize prevention and early diagnosis in the research it supports in the future. "Patients still need better treatments, better prevention, and better early detection," he said. "We must recommit ourselves to answering that call." This recommitment comes in the form of three initiatives--genetic screening of different cancers, developing personalized cancer care drug development platforms, and integrating the work of physical scientists in oncological study--that largely target cancer's molecular roots. Through programs such as the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) and The Cancer Genome Atlas (TCGA), the three year old project on which the NCI collaborates with the National Human Genome Research Institute, researchers hope to identify a slew of genes related to various tumor types, Niederhuber said. TCGA has already identified new genes involved with glioblastoma tumors and has characterized four different subtypes of the deadly cancer. "With that foundation of success, we plan to move TCGA forward, with a goal of identifying all of the relevant genomic alterations in 20 to 25 major tumor types." "We are undoubtedly moving toward the day when cancers will be diagnosed early and controlled," Niederhuber said.
**__Related stories:__***linkurl:Your guide to NIH stimulus funds;http://www.the-scientist.com/blog/display/55588/
[2nd April 2009]*linkurl:How to spend the NIH stimulus;http://www.the-scientist.com/blog/display/55413/
[11th February 2009]*linkurl:Biomedical research is ripe for a stimulus;http://www.the-scientist.com/news/display/55405/
[9th February 2009]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies